血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Angiopoietin 1 (ANGPT1) ,etc. by FLIA (Flow Luminescence Immunoassay)
ANG1; AGP1; AGPT; ANG-I
（注：單次混測多因子不超過8個指標 ）
- 編號ULMA008Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應時長3.5h
- 檢測范圍1.95-2000pg/mL
- 靈敏度最小可檢測劑量小于等于0.65 pg/mL.
- 樣本類型serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標數(shù) 7指標數(shù) 6指標數(shù) 5指標數(shù) 4指標數(shù) 3指標數(shù) 2指標數(shù)1指標數(shù)
- 價格 ¥ 1281 ¥ 1330 ¥ 1404 ¥ 1502 ¥ 1601 ¥ 1749 ¥ 1970 ¥ 2463 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應。
回收率
分別于定值血清及血漿樣本中加入一定量的血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標樣品），重復測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 92-104 | 96 |
| EDTA plasma(n=5) | 80-97 | 83 |
| heparin plasma(n=5) | 81-98 | 95 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 94-102% | 82-103% | 86-104% | 79-103% |
| EDTA plasma(n=5) | 96-105% | 91-98% | 80-98% | 83-98% |
| heparin plasma(n=5) | 85-99% | 82-101% | 81-92% | 84-93% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備；
2. 加樣（標準品、樣本、磁珠）標準品或樣本100μL及磁珠10μL，
37°C酶標板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標準品或標本以及磁珠，其中的血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標記的親和素，再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| URPA008Ra01 | 血管生成素1(ANGPT1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA008Ra01 | 血管生成素1(ANGPT1)多克隆抗體 | WB; IHC |
| UMAA008Ra21 | 血管生成素1(ANGPT1)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA008Ra | 血管生成素1(ANGPT1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA008Ra | 血管生成素1(ANGPT1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Theriogenology | Evaluation of Changes in Doppler Ultrasonography Indices and Levels of Maternal Serum Angiogenic Factors throughout Pregnancy in Ewes [Science: Article] |
| J Atheroscler Thromb | High Mobility Group Box 1 Promotes Angiogenesis from Bone Marrow-derived Endothelial Progenitor Cells after Myocardial Infarction [PubMed: 25735431] |
| Archives of Biological Sciences | Diabetes-induced renal failure is associated with tissue inflammation and neutrophil gelatinase-associated lipocalin: Effects of resveratrol [publication:299492265_Diabetes-induced_renal_failu] |
| Am J Transl Res | Angiopoietin-1 facilitates recovery of hematopoiesis in radiated mice [Pubmed:27347310] |
| Clinical research | Increased plasma concentrations of interleukin 35 in patients with coronary artery disease [Journal:-19] |
| Turkish Journal of Medicl Sciences | A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer [pubmed:28425270] |
| Sci Rep.? | Flunarizine suppresses endothelial Angiopoietin-2 in a calcium - dependent fashion in sepsis. [pubmed:28276491] |
| PeerJ? | The ratio of serum Angiopoietin-1 to Angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker [pubmed:28584715] |
| Molecular&cellular proteomics | Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry [pubmed:28550167] |
| Tumor Biology | Cervical cancer cell–derived angiopoietins promote tumor progression [pubmed:28720059] |
| Free Patents online | RHEUMATOID ARTHRITIS RELATED BIOMARKER [20170350884] |
| Anesthesiology | Vasculotide, an angiopoietin-1 mimetic, restores microcirculatory perfusion and microvascular leakage and decreases fluid resuscitation requirements in?… [Pubmed:28968277] |
| British Journal of Anaesthesia | Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats [10.1016:j.bja.2018.05.049] |
| The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice [Pubmed:29929978] |
| Clinical Significance of Nectin-4 Expression in Metastasis and Angiogenesis for Tumor Relapse [Doi: 10.4143/crt.2018.214] | |
| BIOLOGY?OF?REPRODUCTION | Prostaglandin-mediated effects in early canine corpus luteum: In vivo effects on vascular and immune factors [Pubmed: 30929911] |
| Scientific Reports | Association between Upper-airway Surgery and Ameliorative Risk Markers of endothelial function in obstructive Sleep Apnea [Pubmed: 31882827] |
| Biochem Biophys Res Commun | Effects of interleukin-6 and tumor necrosis factor-α on the expression of angiogenic and collagenolytic factors in premature and mature adipocytes [Pubmed: 32800538] |
| J Nutr Biochem | Effects of protein malnutrition on haematopoietic regulatory activity of bone marrow mesenchymal stem cells [33705953] |
| Intensive Care Med Exp | The effect of targeting Tie2 on hemorrhagic shock-induced renal perfusion disturbances in rats [33997943] |
| Gynecol Endocrinol | Potential of thrombospondin-1 in treatment of polycystic ovary syndrome rat model: a preliminary study [34282706] |
| Yonsei Med J | RAR-Related Orphan Receptor: An Accelerated Preeclampsia Progression by Activating the JAK/STAT3 Pathway [Pubmed:35619579] |
